Contact this trialFirst, we need to learn more about you.
Antiapoptotic Protein Targeted Degradation Compound
DT2216 for Cancer
Recruiting1 awardPhase 1
Chicago, Illinois
This trial is testing a new drug called DT2216 in patients with advanced cancers that haven't responded to other treatments. DT2216 works by breaking down proteins that help cancer cells survive, potentially helping to kill these cells. DT2216 was developed to reduce the toxicity of its predecessor.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service